Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vestal Point Capital LP acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,350,000 shares of the biopharmaceutical company's stock, valued at approximately $31,557,000. Amicus Therapeutics accounts for about 1.9% of Vestal Point Capital LP's investment portfolio, making the stock its 22nd biggest position. Vestal Point Capital LP owned approximately 1.12% of Amicus Therapeutics as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Sovereign s Capital Management LLC bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $2,806,000. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics during the fourth quarter worth about $29,000. Virtus Investment Advisers Inc. bought a new position in Amicus Therapeutics during the fourth quarter worth about $142,000. Squarepoint Ops LLC increased its position in Amicus Therapeutics by 113.4% during the fourth quarter. Squarepoint Ops LLC now owns 1,417,152 shares of the biopharmaceutical company's stock worth $13,350,000 after acquiring an additional 753,060 shares during the period. Finally, Two Sigma Advisers LP increased its position in Amicus Therapeutics by 86.7% during the fourth quarter. Two Sigma Advisers LP now owns 111,976 shares of the biopharmaceutical company's stock worth $1,055,000 after acquiring an additional 52,000 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on FOLD shares. The Goldman Sachs Group lowered their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Price Performance

Shares of FOLD traded down $0.04 during mid-day trading on Friday, reaching $6.22. The company had a trading volume of 2,822,292 shares, compared to its average volume of 2,841,418. The company's 50 day simple moving average is $7.11 and its 200 day simple moving average is $8.74. Amicus Therapeutics, Inc. has a 1-year low of $5.81 and a 1-year high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -34.56, a P/E/G ratio of 1.51 and a beta of 0.64.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.